3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Prostatic Neoplasms
134
Breast Neoplasms
91
Neoplasms
8
Breast Neoplasms, Male
6
Neoplasm Metastasis
5
Advanced Breast Cancer
4
Salivary Gland Neoplasms
3
Prostate Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Osteoporosis
2
Leiomyoma
2
Infertility
2
Advanced Prostate Cancer
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Radiation Injuries
1
Primary Ovarian Insufficiency
1
Primary Dysautonomias
1
Patients With T1-4 Advanced Prostate Cancer
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Osteitis Deformans
1
Myofibroma
1
Lymphatic Metastasis
1
Kidney Diseases
1
Inflammatory Breast Neoplasms
1
Hypertension
1
Hyperlipidemias
1
Interventions
Epoetin Alfa
53
Darbepoetin alfa
38
epoetin beta
12
ferric carboxymaltose
11
Lenalidomide
5
Cyclophosphamide
5
luspatercept
4
fludarabine phosphate
4
fludarabine
4
Erythropoietin
4
Cyclosporine
4
Cisplatin
4
Busulfan
4
Blood Transfusion
4
ACE-011
4
peginesatide
3
iron isomaltoside 1000
3
hematide
3
ferrous sulfate
3
ferric gluconate
3
Radiotherapy
3
Iron-Dextran Complex
3
Filgrastim
3
Ferric Oxide, Saccharated
3
Biopsy
3
Antilymphocyte Serum
3
thymoglobulin
2
telapristone acetate
2
ruxolitinib
2
ferrous fumarate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Anemia
×
Goserelin
×
Clear all
NCT00303784
2020-11-27
PATCH
University College, London
Phase 3
Unknown
2,200 enrolled